查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
细胞活力测定市场规模、份额和趋势分析报告：按产品（消耗品、仪器）、应用（药物发现与开发、干细胞研究）、最终用户、地区、细分市场预测 2023-2030 年
市场调查报告书
商品编码
1171087

细胞活力测定市场规模、份额和趋势分析报告：按产品（消耗品、仪器）、应用（药物发现与开发、干细胞研究）、最终用户、地区、细分市场预测 2023-2030 年

Cell Viability Assays Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments), By Application (Drug Discovery & Development, Stem Cell Research), By End-user, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

细胞活力检测市场的增长和趋势

根据 Grand View Research, Inc. 的最新报告，到 2030 年，细胞活力检测的全球市场规模预计将达到 30.1 亿美元，2023 年至 2030 年的复合年增长率为 9.94%。我来了。 慢性病和传染病患病率的上升以及对基于细胞的疗法的日益关注正在增加市场的增长前景。 此外，增加对基于细胞的研究的资助和增加自动化设备的使用是推动细胞活力测定 (CVA) 市场的主要因素。

基于细胞的研究不断增加的资金和投资正在扩大细胞存活测定的增长前景。 例如，2022 年 5 月，加州再生医学研究所 (CIRM) 宣布投资 1100 万美元用于测试细胞疗法临床试验，以帮助喉癌患者从放射疗法的毁灭性副作用中痊癒。 因此，增加对基于细胞的研究的资助预计将在预测期内促进市场增长。

此外，领先的公司不断开发尖端技术以满足不断增长的需求并抓住尚未开发的机会。 例如，2022 年 4 月，Molecular Devices, LLC 宣布推出 SpectraMax Mini 多模式微孔板读板机，适用于包括细胞活力在内的多种应用。 它是一种紧凑、经济高效的解决方案，集成了数据分析软件和协议控制，可实现快速数据生成和分析。 预计此类创新将推动 CVA 在生物技术和学术实验室中的采用。

预计 COVID-19 的爆发将对市场增长产生积极影响。 细胞计数和活力测定用于支持 COVID-19 疫苗研究。 COVID-19 研究中最常用的 CVA 包括活/死（EarlyTox 活/死检测试剂盒）染色、MTT 检测、转染效率和细胞活力（CellTiter-Glo 发光细胞活力检测）。 因此，预计 COVID-19 流行病将增加这些检测的使用，这有望促进市场增长。

对开发基于细胞的疗法的日益关注正在推动市场的增长。 增加临床试验、FDA 批准和主要参与者的合作伙伴关係等战略举措正在推动市场增长。 例如，2022 年 1 月，百时美施贵宝 (Bristol-Myers Squibb) 和 Century Therapeutics 展开研究合作，开发四种用于血液恶性肿瘤和实体瘤的诱导多能干细胞。 这些努力有望增加 CVA 在干细胞疗法开发中的应用，推动预测期内的增长。

另一方面，试剂的高成本和细胞活力测定在 3D 细胞培养中的应用有限可能会在一定程度上限制市场增长。 例如，在 3D 细胞培养中进行细胞活力测定时，测定试剂可能很难到达微组织的中心。 因此，无法获得准确的测量结果。 然而，主要参与者正在不断努力开发新颖且具有成本效益的试剂和技术来克服这一限制，这将为市场创造增长前景。

细胞活力检测市场报告要点

按产品划分，耗材部分在 2022 年所占份额最大。 这是由于製药和生物技术公司、干细胞研究和诊断对 CVA 的需求不断增加，这反过来将推动市场增长。

从应用来看，2022年药物发现与开发领域将占据第二大份额。 这是因为越来越多地使用 CVA 来估计药物发现和开发过程中与细胞死亡相关的细胞变化。

在最终用户方面，生物製药和製药公司部门将在 2022 年占据最大份额，因为细胞活力测定在药物中广泛使用，以评估开发药物对细胞的影响。占

由于政府投资举措的增加、癌症等慢性病发病率的增加以及用于临床和实验室研究的高质量基础设施的存在，北美将在 2022 年占据超过 35.0% 的份额。主导着世界市场。

由于对新疗法的需求不断增加、政府增加研发投资以及基础设施的快速发展，预计亚太地区未来将经历显着增长。

内容

第1章研究方法论

  • 市场细分和范围
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 初步调查的详细信息
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细信息
    • 商品流分析
      • 方法 1：商品流方法
      • 方法 2：使用自下而上的方法逐个国家/地区进行市场估算
  • 全球市场：CAGR 计算
  • 调查假设
  • 二级信息列表
  • 主要信息列表
  • 目的
  • 缩写列表

第2章市场定义

第 3 章执行摘要

  • 市场概览

第 4 章全球细胞活力测定市场变量、趋势和范围

  • 细胞活力检测市场谱系展望
    • 母公司市场展望
  • 描绘渗透率和增长前景
  • 监管框架
  • 市场驱动因素分析
    • 人们对开发基于细胞的疗法越来越感兴趣
    • 增加对细胞研究的资助
    • 细胞活力测定的技术进步
  • 市场製约因素分析
    • 试剂和设备的高成本可能会限制细胞活力测定的采用
    • 细胞活力测定对 3D 细胞培养的适用性有限
  • 市场机会分析
    • 越来越关注干细胞研究
  • 波特的五力分析
  • 细胞活力检测市场：COVID-19 影响分析

第 5 章细胞活力测定市场 - 细分分析，副产品，2018-2030（百万美元）

  • 全球细胞活力检测市场：产品差异分析
  • 消耗品
    • 试剂和检测试剂盒
      • 染料排斥分析
      • 比色法
      • 荧光分析
      • 发光分析
    • 微孔板
  • 设备
    • 分光光度计
    • 显微镜
    • 细胞图像分析系统
    • 流式细胞仪
    • 其他

第 6 章细胞活力检测市场 - 细分分析，按应用，2018-2030（百万美元）

  • 全球细胞存活分析市场：应用差异分析
  • 药物发现和开发
  • 干细胞研究
  • 诊断

第 7 章细胞活力测定市场细分分析，按最终用户，2018-2030 年（百万美元）

  • 细胞活力检测市场：最终用户差异分析
  • 生物製药和製药公司
  • CRO 和 CMO
  • 学术和研究机构
  • 诊断实验室

第 8 章细胞活力检测市场：-按地区划分的细分分析，2018-2030 年（百万美元）

  • 细胞存活分析市场：区域差异分析
  • 北美
    • SWOT 分析
    • 美国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 加拿大
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 欧洲
    • SWOT 分析
    • 德国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 英国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 法国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 意大利
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 西班牙
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 丹麦
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 瑞典
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 挪威
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 亚太地区
    • SWOT 分析
    • 日本
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 中国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 印度
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 韩国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 澳大利亚
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 泰国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 拉丁美洲
    • SWOT 分析
    • 巴西
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 墨西哥
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 阿根廷
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 中东和非洲
    • SWOT 分析
    • 南非
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 沙特阿拉伯
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 阿拉伯联合酋长国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 科威特
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景

第9章竞争格局

  • 市场进入者概览
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories Inc.
    • Merck KGaA
    • BD
    • PerkinElmer Inc.
    • Promega Corporation
    • Biotium
    • Creative Bioarray
    • Abcam Plc
    • Charles River Laboratories
  • 财务业绩
  • 参与者分类
    • 市场领导者
      • 2022 年细胞活力检测市场份额分析
    • 战略规划
      • 分机
      • 得到
      • 协作
      • 产品/服务发布
      • 伙伴关係
      • 其他
Product Code: GVR-4-68040-008-0

Cell Viability Assays Market Growth & Trends:

The global cell viability assays market size is expected to reach USD 3.01 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.94% from 2023 to 2030. The rising prevalence of chronic and infectious diseases and the increasing focus on cell-based therapeutics are expanding the growth prospects of the market. In addition, growing funding for cell-based research and increasing use of automated instruments are the key factors driving the market for cell viability assays (CVAs).

Increasing funding and investments for cell-based research are expanding growth prospects for cell viability assays. For instance, in May 2022, the California Institute for Regenerative Medicine (CIRM) announced an investment of USD 11 million to fund a cell therapy clinical trial testing to help throat cancer patients to heal from the devastating side effects of radiation therapy. Thus, increasing funding for cell-based research is predicted to boost market growth during the projection period.

Furthermore, major players are continuously developing sophisticated technologies to meet the rising demand and capture untapped opportunities. For instance, in April 2022, Molecular Devices, LLC introduced SpectraMax Mini Multi-Mode Microplate Reader for various applications, including cell viability. It is a compact and cost-effective solution integrated with data analysis software and protocol control for rapid data generation and analysis. Such technological innovations are anticipated to increase the adoption of CVAs in biotech and academic laboratories.

The COVID-19 pandemic is expected to positively influence market growth. The cell counting and viability assay are used to aid COVID-19 vaccine research. The most frequently used CVAs in COVID-19 research include Live/Dead (EarlyTox Live/Dead Assay Kit) staining, MTT assay, Transfection efficiency, and Cell viability (CellTiter-Glo Luminescent Cell Viability Assay). As a result, the usage of these assays is projected to increase due to the COVID-19 pandemic, which, in turn, is anticipated to boost the market growth.

The rising focus on the development of cell-based therapeutics is accelerating market growth. Increasing clinical trials, FDA approvals, and strategic initiatives such as collaborations by major players are boosting the market growth. For instance, in January 2022, Bristol Myers Squibb and Century Therapeutics entered into a research collaboration to develop four induced pluripotent stem cells for hematologic malignancies and solid tumors. Such initiatives are projected to increase the application of CVAs during the development of stem cell therapeutics, thereby propelling growth during the forecast years.

On the other hand, the high cost of reagents and limitations in the applicability of cell viability assay for 3D cell culture may restrict the market growth to a certain extent. For instance, while performing the cell viability assay in 3D cell culture, the assay regents may have difficulty reaching the center of microtissues. Thus, accurate results of the assay cannot be determined. However, key players are continuously striving for developing novel and cost-effective reagents and techniques to overcome the limitations, which is likely to create growth prospects for the market.

Cell Viability Assays Market Report Highlights:

  • By product, the consumables segment held the largest share in 2022. This is attributed to the increase in the requirement of CVAs for pharmaceutical and biotechnology companies, stem cell research, and diagnostics, which, in turn, is likely to fuel the market growth
  • By application, the drug discovery and development segment held the second-largest share in 2022. This is attributed to an increase in the applications of CVAs to estimate the cellular variations related to cell death during the drug discovery and development
  • By end-user, the biopharmaceutical and pharmaceutical companies segment held the largest share in 2022 owing to the widespread use of cell viability assay in pharmaceuticals to evaluate the influence of developed agents on cells
  • North America dominated the global market with over 35.0% share in 2022 due to a rise in investment initiatives by the government, increasing incidence of chronic diseases such as cancer, and the presence of high-quality infrastructure for clinical and laboratory research
  • Asia Pacific is expected to grow considerably in the future owing to the rising demand for novel therapeutics, increasing R&D investment by governments, and rapid infrastructural development

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity flow approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using a bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List of Abbreviations

Chapter 2 Market Definitions

Chapter 3 Executive Summary

  • 3.1 Market Summary

Chapter 4 Global Cell Viability Assay Market Variables, Trends, & Scope

  • 4.1 Cell Viability Assay Market Lineage Outlook
    • 4.1.1 Parent Market Outlook
  • 4.2 Penetration and Growth Prospect Mapping
  • 4.3 Regulatory Framework
  • 4.4 Market Driver Analysis
    • 4.4.1 Rising focus on the development of cell-based therapeutics
    • 4.4.2 Growing funding for cell-based research
    • 4.4.3 Technological advancements in cell viability assays
  • 4.5 Market Restraint Analysis
    • 4.5.1 High cost of reagents and instruments may limit the adoption of cell viability assays
    • 4.5.2 Limitations in the applicability of cell viability assays for 3D cell culture
  • 4.6 Market Opportunity Analysis
    • 4.6.1 Growing emphasis on stem cell research
  • 4.7 Porter's Five Forces Analysis
  • 4.8 Cell Viability Assay Market: COVID-19 Impact Analysis

Chapter 5 Cell Viability Assay Market - Segment Analysis, by product, 2018 - 2030 (USD Million)

  • 5.1 Global Cell Viability Assay Market: Product Movement Analysis
  • 5.2 Consumables
    • 5.2.1 Consumables market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.2.2 Reagents and Assay Kits
      • 5.2.2.1 Reagents and assay kits, by type market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.2.2.2 Dye exclusion assays
      • 5.2.2.2.1 Dye exclusion assays market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.2.2.3 Colorimetric assays
      • 5.2.2.3.1 Colorimetric assays market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.2.2.4 Fluorometric assays
      • 5.2.2.4.1 Fluorometric assays market estimates and forecast, 2018 - 2030 (USD Million)
      • 5.2.2.5 Luminometric assays
      • 5.2.2.5.1 Luminometric assays market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.2.3 Microplates
      • 5.2.2.1 Microplates market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3 Instruments
    • 5.3.1 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.2 Spectrophotometer
      • 5.3.2.1 Spectrophotometer market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.3 Microscopy
      • 5.3.3.1 Microscopy market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.4 Cell Imaging and Analysis System
      • 5.3.4.1 Cell imaging and analysis system market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.5 Flow Cytometry
      • 5.3.5.1 Flow cytometry market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.6 Others
      • 5.3.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Cell Viability Assay Market- Segment Analysis, by Application, 2018 - 2030 (USD Million)

  • 6.1 Global Cell Viability Assay Market: Application Movement Analysis
  • 6.2 Drug Discovery and Development
    • 6.2.1 Drug discovery and development market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3 Stem Cell Research
    • 6.3.1 Stem cell research market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4 Diagnostics
    • 6.4.1 Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Cell Viability Assay Market- Segment Analysis, by End-user, 2018 - 2030 (USD Million)

  • 7.1 Cell Viability Assay Market: End-user Movement Analysis
  • 7.2 Biopharmaceutical & Pharmaceutical Companies
    • 7.2.1 Biopharmaceutical & pharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3 CROs & CMOs
    • 7.3.1 CROs & CMOs market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4. Academic & Research Institutes
    • 7.4.1 Academic & research institutes market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5. Diagnostic Labs
    • 7.5.1 Diagnostic labs market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Cell Viability Assay Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)

  • 8.1 Cell Viability Assay Market: Regional Movement Analysis
  • 8.2 North America
    • 8.2.1 SWOT Analysis
      • 8.2.1.1 North America cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.2.1.2 North America cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.2.1.3 North America cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.2.2 U.S.
      • 8.2.2.1 Key Country Dynamics
      • 8.2.2.2 Target Disease Prevalence
      • 8.2.2.3 Competitive Scenario
      • 8.2.2.4 Regulatory Framework
      • 8.2.2.5 Reimbursement Scenario
      • 8.2.2.6 U.S. cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.2.2.7 U.S. cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.2.2.8 U.S. cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.2.3 Canada
      • 8.2.3.1 Key Country Dynamics
      • 8.2.3.2 Target Disease Prevalence
      • 8.2.3.3 Competitive Scenario
      • 8.2.3.4 Regulatory Framework
      • 8.2.3.5 Reimbursement Scenario
      • 8.2.3.6 Canada cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.2.3.7 Canada cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.2.3.8 Canada cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.3 Europe
    • 8.3.1 SWOT Analysis
      • 8.3.1.1 Europe cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.1.2 Europe cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.1.4 Europe cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.2 Germany
      • 8.3.2.1 Key Country Dynamics
      • 8.3.2.2 Target Disease Prevalence
      • 8.3.2.3 Competitive Scenario
      • 8.3.2.4 Regulatory Framework
      • 8.3.2.5 Reimbursement Scenario
      • 8.3.2.6 Germany cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.2.7 Germany cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.2.8 Germany cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.3 U.K.
      • 8.3.3.1 Key Country Dynamics
      • 8.3.3.2 Target Disease Prevalence
      • 8.3.3.3 Competitive Scenario
      • 8.3.3.4 Regulatory Framework
      • 8.3.3.5 Reimbursement Scenario
      • 8.3.3.6 U.K. cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.3.7 U.K. cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.3.8 U.K. cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.4 France
      • 8.3.4.1 Key Country Dynamics
      • 8.3.4.2 Target Disease Prevalence
      • 8.3.4.3 Competitive Scenario
      • 8.3.4.4 Regulatory Framework
      • 8.3.4.5 Reimbursement Scenario
      • 8.3.4.6 France cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.4.7 France cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.4.8 France cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.5 Italy
      • 8.3.5.1 Key Country Dynamics
      • 8.3.5.2 Target Disease Prevalence
      • 8.3.5.3 Competitive Scenario
      • 8.3.5.4 Regulatory Framework
      • 8.3.5.5 Reimbursement Scenario
      • 8.3.5.6 Italy cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.5.7 Italy cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.5.8 Italy cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.6 Spain
      • 8.3.6.1 Key Country Dynamics
      • 8.3.6.2 Target Disease Prevalence
      • 8.3.6.3 Competitive Scenario
      • 8.3.6.4 Regulatory Framework
      • 8.3.6.5 Reimbursement Scenario
      • 8.3.6.6 Spain cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.6.7 Spain cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.6.8 Spain cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.7 Denmark
      • 8.3.7.1 Key Country Dynamics
      • 8.3.7.2 Target Disease Prevalence
      • 8.3.7.3 Competitive Scenario
      • 8.3.7.4 Regulatory Framework
      • 8.3.7.5 Reimbursement Scenario
      • 8.3.7.6 Denmark cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.7.7 Denmark cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.7.8 Denmark cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.8 Sweden
      • 8.3.8.1 Key Country Dynamics
      • 8.3.8.2 Target Disease Prevalence
      • 8.3.8.3 Competitive Scenario
      • 8.3.8.4 Regulatory Framework
      • 8.3.8.5 Reimbursement Scenario
      • 8.3.8.6 Sweden cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.8.7 Sweden cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.8.8 Sweden cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.9 Norway
      • 8.3.9.1 Key Country Dynamics
      • 8.3.9.2 Target Disease Prevalence
      • 8.3.9.3 Competitive Scenario
      • 8.3.9.4 Regulatory Framework
      • 8.3.9.5 Reimbursement Scenario
      • 8.3.9.6 Norway cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.3.9.7 Norway cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.3.9.8 Norway cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 SWOT Analysis
      • 8.4.1.1 Asia Pacific cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.1.2 Asia Pacific cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.1.3 Asia Pacific cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.2 Japan
      • 8.4.2.1 Key Country Dynamics
      • 8.4.2.2 Target Disease Prevalence
      • 8.4.2.3 Competitive Scenario
      • 8.4.2.4 Regulatory Framework
      • 8.4.2.5 Reimbursement Scenario
      • 8.4.2.6 Japan cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.2.7 Japan cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.2.8 Japan cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.3 China
      • 8.4.3.1 Key Country Dynamics
      • 8.4.3.2 Target Disease Prevalence
      • 8.4.3.3 Competitive Scenario
      • 8.4.3.4 Regulatory Framework
      • 8.4.3.5 Reimbursement Scenario
      • 8.4.3.6 China cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.3.7 China cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.3.8 China cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.4 India
      • 8.4.4.1 Key Country Dynamics
      • 8.4.4.2 Target Disease Prevalence
      • 8.4.4.3 Competitive Scenario
      • 8.4.4.4 Regulatory Framework
      • 8.4.4.5 Reimbursement Scenario
      • 8.4.4.6 India cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.4.7 India cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.4.8 India cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.5 South Korea
      • 8.4.5.1 Key Country Dynamics
      • 8.4.5.2 Target Disease Prevalence
      • 8.4.5.3 Competitive Scenario
      • 8.4.5.4 Regulatory Framework
      • 8.4.5.5 Reimbursement Scenario
      • 8.4.5.6 South Korea cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.5.7 South Korea cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.5.8 South Korea cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.6 Australia
      • 8.3.9.1 Key Country Dynamics
      • 8.4.6.2 Target Disease Prevalence
      • 8.4.6.3 Competitive Scenario
      • 8.4.6.4 Regulatory Framework
      • 8.4.6.5 Reimbursement Scenario
      • 8.4.6.6 Australia cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.6.7 Australia cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.6.8 Australia cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.7 Thailand
      • 8.4.7.1 Key Country Dynamics
      • 8.4.7.2 Target Disease Prevalence
      • 8.4.7.3 Competitive Scenario
      • 8.4.7.4 Regulatory Framework
      • 8.4.7.5 Reimbursement Scenario
      • 8.4.7.6 Thailand cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.4.7.7 Thailand cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.4.7.8 Thailand cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.5 Latin America
    • 8.5.1 SWOT Analysis
      • 8.5.1.1 Latin America cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.5.1.2 Latin America cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.5.1.3 Latin America cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.5.2 Brazil
      • 8.5.2.1 Key Country Dynamics
      • 8.5.2.2 Target Disease Prevalence
      • 8.5.2.3 Competitive Scenario
      • 8.5.2.4 Regulatory Framework
      • 8.5.2.5 Reimbursement Scenario
      • 8.5.2.6 Brazil cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.5.2.7 Brazil cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.5.2.8 Brazil cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.5.3 Mexico
      • 8.5.3.1 Key Country Dynamics
      • 8.5.3.2 Target Disease Prevalence
      • 8.5.3.3 Competitive Scenario
      • 8.5.3.4 Regulatory Framework
      • 8.5.3.5 Reimbursement Scenario
      • 8.5.3.6 Mexico cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.5.3.7 Mexico cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.5.3.8 Mexico cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.5.4 Argentina
      • 8.5.4.1 Key Country Dynamics
      • 8.5.4.2 Target Disease Prevalence
      • 8.5.4.3 Competitive Scenario
      • 8.5.4.4 Regulatory Framework
      • 8.5.4.5 Reimbursement Scenario
      • 8.5.4.6 Argentina cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.5.4.7 Argentina cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.5.4.8 Argentina cell viability assay market, by end-user, 2018 - 2030 (USD Million)
  • 8.6 MEA
    • 8.6.1 SWOT Analysis
      • 8.6.1.1 MEA cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.6.1.2 MEA cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.6.1.3 MEA cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.2 South Africa
      • 8.6.4.1 Key Country Dynamics
      • 8.6.2.2 Target Disease Prevalence
      • 8.6.2.3 Competitive Scenario
      • 8.6.2.4 Regulatory Framework
      • 8.6.2.5 Reimbursement Scenario
      • 8.6.2.6 Argentina cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.6.2.7 Argentina cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.6.2.8 Argentina cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.3 Saudi Arabia
      • 8.6.3.1 Key Country Dynamics
      • 8.6.3.2 Target Disease Prevalence
      • 8.6.3.3 Competitive Scenario
      • 8.6.3.4 Regulatory Framework
      • 8.6.3.5 Reimbursement Scenario
      • 8.6.3.6 Saudi Arabia cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.6.3.7 Saudi Arabia cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.6.3.8 Saudi Arabia cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.4 UAE
      • 8.6.4.1 Key Country Dynamics
      • 8.6.4.2 Target Disease Prevalence
      • 8.6.4.3 Competitive Scenario
      • 8.6.4.4 Regulatory Framework
      • 8.6.4.5 Reimbursement Scenario
      • 8.6.4.6 UAE cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.6.4.7 UAE cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.6.4.8 UAE cell viability assay market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.5 Kuwait
      • 8.6.5.1 Key Country Dynamics
      • 8.6.5.2 Target Disease Prevalence
      • 8.6.5.3 Competitive Scenario
      • 8.6.5.4 Regulatory Framework
      • 8.6.5.5 Reimbursement Scenario
      • 8.6.5.6 Kuwait cell viability assay market, by product, 2018 - 2030 (USD Million)
      • 8.6.5.7 Kuwait cell viability assay market, by application, 2018 - 2030 (USD Million)
      • 8.6.5.8 Kuwait cell viability assay market, by end-user, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Participant's overview
    • 9.1.1 Thermo Fisher Scientific Inc.
    • 9.1.2 Agilent Technologies, Inc.
    • 9.1.3 Bio-Rad Laboratories Inc.
    • 9.1.4 Merck KGaA
    • 9.1.5 BD
    • 9.1.6 PerkinElmer Inc.
    • 9.1.7 Promega Corporation
    • 9.1.8 Biotium
    • 9.1.9 Creative Bioarray
    • 9.1.10 Abcam Plc
    • 9.1.11 Charles River Laboratories
  • 9.2 Financial performance
  • 9.3 Participant categorization
    • 9.3.1 Market leaders
      • 9.3.1.1 Cell viability assay market share analysis, 2022
    • 9.3.2 Strategy mapping
      • 9.3.2.1 Expansion
      • 9.3.2.2 Acquisition
      • 9.3.2.3 Collaborations
      • 9.3.2.4 Product/service launch
      • 9.3.2.5 Partnerships
      • 9.3.2.6 Others

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 4. Global cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 5. Global cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 6. Global cell viability assay market, by region, 2018 - 2030 (USD Million)
  • Table 7. North America cell viability assay market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 9. North America cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 10. North America cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 11. U.S. Cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 12. U.S. Cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 13. U.S. Cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 14. Canada cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 15. Canada cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 16. Canada cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 17. Europe cell viability assay market, by country, 2018 - 2030 (USD Million)
  • Table 18. Europe cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 19. Europe cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 20. Europe cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 21. U.K. cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 22. U.K. cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 23. U.K. cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 24. Germany cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 25. Germany cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 26. Germany cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 27. France cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 28. France cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 29. France cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 30. Italy cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 31. Italy cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 32. Italy cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 33. Spain cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 34. Spain cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 35. Spain cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 36. Denmark cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 37. Denmark cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 38. Denmark cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 39. Sweden cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 40. Sweden cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 41. Sweden cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 42. Norway cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 43. Norway cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 44. Norway cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 45. Asia Pacific cell viability assay market, by country, 2018 - 2030 (USD Million)
  • Table 46. Asia Pacific cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 47. Asia Pacific cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 48. Asia pacific cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 49. China cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 50. China cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 51. China cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 52. India cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 53. India cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 54. India cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 55. Japan cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 56. Japan cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 57. Japan cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 58. Thailand cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 59. Thailand cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 60. Thailand cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 61. Australia cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 62. Australia cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 63. Australia cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 64. South Korea cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 65. South Korea cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 66. South Korea cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 67. Latin America cell viability assay market, by country, 2018 - 2030 (USD Million)
  • Table 68. Latin America cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 69. Latin America cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 70. Latin America cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 71. Brazil cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 72. Brazil cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 73. Brazil cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 74. Mexico cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 75. Mexico cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 76. Mexico cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 77. Argentina cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 78. Argentina cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 79. Argentina cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa cell viability assay market, by country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 84. South Africa cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 85. South Africa cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 86. South Africa cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 90. UAE cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 91. UAE cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 92. UAE cell viability assay market, end-user, 2018 - 2030 (USD Million)
  • Table 93. Kuwait cell viability assay market, by product, 2018 - 2030 (USD Million)
  • Table 94. Kuwait cell viability assay market, by application, 2018 - 2030 (USD Million)
  • Table 95. Kuwait cell viability assay market, end-user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Cell viability assay, market segmentation
  • Fig. 8 Market snapshot, 2021
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Market challenge relevance analysis (current & future impact)
  • Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Market penetration vs growth prospect mapping, 2021
  • Fig. 16 Global cell viability assay market: product movement analysis
  • Fig. 17 Global cell viability assay market, for consumables, 2018 - 2030 (USD Million)
  • Fig. 18 Global cell viability assay market, for reagents and assay kits, by type, 2018 - 2030 (USD Million)
  • Fig. 19 Global cell viability assay market, for dye exclusion assays, 2018 - 2030 (USD Million)
  • Fig. 20 Global cell viability assay market, for colorimetric assays, 2018 - 2030 (USD Million)
  • Fig. 21 Global cell viability assay market, for fluorometric assays, 2018 - 2030 (USD Million)
  • Fig. 22 Global cell viability assay market, for luminometric assays, 2018 - 2030 (USD Million)
  • Fig. 23 Global cell viability assay market, for microplates, 2018 - 2030 (USD Million)
  • Fig. 24 Global cell viability assay market, for insturments, 2018 - 2030 (USD Million)
  • Fig. 25 Global cell viability assay market, for spectrophotometer, 2018 - 2030 (USD Million)
  • Fig. 26 Global cell viability assay market, for microscopy, 2018 - 2030 (USD Million)
  • Fig. 27 Global cell viability assay market, for cell imaging and analysis system, 2018 - 2030 (USD Million)
  • Fig. 28 Global cell viability assay market, for others, 2018 - 2030 (USD Million)
  • Fig. 29 Global cell viability assay market, for microplates, 2018 - 2030 (USD Million)
  • Fig. 30 Global cell viability assay market: application movement analysis
  • Fig. 31 Global cell viability assay market, for drug discovery and development, 2018 - 2030 (USD Million)
  • Fig. 32 Global cell viability assay market, for stem cell research, 2018 - 2030 (USD Million)
  • Fig. 33 Global cell viability assay market, for stem cell research, 2018 - 2030 (USD Million)
  • Fig. 34 Global cell viability assay market: end-user movement analysis
  • Fig. 35 Global cell viability assay market, for biopharmaceutical & pharmaceutical companies, 2018 - 2030 (USD Million)
  • Fig. 36 Global cell viability assay market, for CROSs & CMOs, 2018 - 2030 (USD Million)
  • Fig. 37 Global cell viability assay market, for academic & research institutes, 2018 - 2030 (USD Million)
  • Fig. 38 Global cell viability assay market, for diagnostic labs, 2018 - 2030 (USD Million)
  • Fig. 39 Regional marketplace: key takeaways
  • Fig. 40 Regional outlook, 2021 & 2030
  • Fig. 41 Global flow cytometry market: regional movement analysis
  • Fig. 42 North America cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 44 Canada cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 45 Europe cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 46 U.K. cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 47 Germany cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 48 France cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia pacific cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 55 China cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 56 India cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 57 Japan cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 61 Latin America cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 62 Brazil cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 63 Mexico cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 64 Argentina cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 65 Middle East and Africa cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 67 Saudi Arabia cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 68 UAE cell viability assay market, 2018 - 2030 (USD Million)
  • Fig. 69 Kuwait cell viability assay market, 2018 - 2030 (USD Million)